| Literature DB >> 25409346 |
Paul B Lawrence1, Yulian Gavrilov, Sam S Matthews, Minnie I Langlois, Dalit Shental-Bechor, Harry M Greenblatt, Brijesh K Pandey, Mason S Smith, Ryan Paxman, Chad D Torgerson, Jacob P Merrell, Cameron C Ritz, Maxim B Prigozhin, Yaakov Levy, Joshua L Price.
Abstract
PEGylation of protein side chains has been used for more than 30 years to enhance the pharmacokinetic properties of protein drugs. However, there are no structure- or sequence-based guidelines for selecting sites that provide optimal PEG-based pharmacokinetic enhancement with minimal losses to biological activity. We hypothesize that globally optimal PEGylation sites are characterized by the ability of the PEG oligomer to increase protein conformational stability; however, the current understanding of how PEG influences the conformational stability of proteins is incomplete. Here we use the WW domain of the human protein Pin 1 (WW) as a model system to probe the impact of PEG on protein conformational stability. Using a combination of experimental and theoretical approaches, we develop a structure-based method for predicting which sites within WW are most likely to experience PEG-based stabilization, and we show that this method correctly predicts the location of a stabilizing PEGylation site within the chicken Src SH3 domain. PEG-based stabilization in WW is associated with enhanced resistance to proteolysis, is entropic in origin, and likely involves disruption by PEG of the network of hydrogen-bound solvent molecules that surround the protein. Our results highlight the possibility of using modern site-specific PEGylation techniques to install PEG oligomers at predetermined locations where PEG will provide optimal increases in conformational and proteolytic stability.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25409346 DOI: 10.1021/ja5095183
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419